Sector News

Drugmaker Actelion in ‘strategic transaction’ talks with ZS Pharma

September 11, 2015
Life sciences

(Reuters) – Switzerland-based drugmaker Actelion Ltd (ATLN.VX) said on Thursday it has initiated preliminary discussions with U.S. biotech company ZS Pharma Inc (ZSPH.O).

Bloomberg had reported earlier in the day that Actelion had offered to buy ZS Pharma last month in a deal valued at $2.5 billion.

Actelion and ZS Pharma both issued statements confirming that the two companies had held preliminary discussions, but did not specifically mention if the talks were related to a buyout.

ZS Pharma said the talks were “regarding a potential strategic transaction” and Actelion said the talks were “without any commitment on either party”.

ZS Pharma’s shares had spiked nearly 46 percent to touch a record high of $84.85 after the Bloomberg report. They closed up 28.4 percent, valuing the company at $1.9 billion.

San Mateo, California-based ZS Pharma’s lead experimental drug, ZS-9, is aimed at treating hyperalkemia, a build up of potassium in the body that could lead to heart failure.

The company filed a marketing application for ZS-9 with the U.S. Food and Drug Administration in May. The FDA is expected to issue a ruling on the application in May next year.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.